Did you know that even if you are not interested in being in a clinical trial, DuchenneConnect is still a powerful tool that is useful for people with Duchenne and Becker? That’s right! DuchenneConnect is the largest, most robust patient report registry for Duchenne and Becker in the United…

PPMD is proud to have been chosen by American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC) to help create a new interactive tool,…

Urge your Lawmakers to Sign the FY 17 Duchenne Appropriations Letter!

Today and tomorrow, scores of PPMD advocates will be on Capitol Hill to urge their Senators and Members of Congress to continue…

Capricor Therapeutics announced continuing enrollment of, and the treatment of the first patient with Duchenne-related cardiomyopathy with CAP-1002 in the HOPE-Duchenne Phase I/II clinical trial. This is an exciting next step in the  progress of CAP-1002, an allogeneic, cardiosphere-derived stem cell (CDC) therapy.

As you may recall, PPMD hosted a webinar with Capricor last month. Click below to watch the webinar,…

It seems that everyone is looking for the newest molecule, the newest therapy, the newest technique that will halt the progression of Duchenne. This is good and we should continue on this journey. But none of these novel treatments will get to patients without first going through a rigorous…

It is a sadly familiar story: the parent moves the child, the child gets bumped/dropped, the child complains that something hurts (but doesn't really hurt so badly that a broken bone is suspected), and everyone goes on about their business.

Then, the child may become sleepier than…

Thanks to this incredible community urging lawmakers, well over 100 Members of Congress signed and submitted a letter …

Medication-related osteonecrosis of the jaw (MRONJ),  or osteonecrosis of the jaw (ONJ), is a condition that results when the bones of the jaw are exposed and then do not heal – generally when a tooth is removed. It…

This year’s already action-packed Advocacy Conference, February 21-23 welcomes a special Gene Therapy Forum on Monday, February 22…

For nearly two years, PPMD has been working with Congressional champions and industry partners to help lead an effort to streamline the regulatory pathways and review processes for targeted therapeutics (which would include such things as ‘follow on exons’) by clarifying the FDA’s existing authority to leverage data previously used in the approval of a targeted product when approving a new therapy. These efforts have yielded a provision in the House of Representatives…

Summit Therapeutics’ SMT C1100 is a small molecule drug that targets increasing the production of utrophin. Utrophin is a protein that is present in early muscle development but “switched off” as muscle fibers mature and dystrophin is produced.…

Sarepta Therapeutics received notification of a PDUFA extension for the FDA's review of eteplirsen. The PDUFA date was extended by an…

Lilly has now completed one of the largest clinical trials in Duchenne (330 patients) with disappointing results. Today the company reports that their Phase 3 study of tadalafil failed to provide evidence for efficacy in slowing decline in walking ability in boys with Duchenne. Subsequently, the company has made the decision to discontinue the open-label extension. The full update to the community is below.

Sadly, this is one more blow for this community. We are deeply…

The UK has instituted new regulations around shipping medications out of the country.  The UK is now requiring companies to provide proof of drugs that they have exported overseas.  In order to be compliant, Masters Marketing will begin to ship deflazacort, and other drugs, using trackable service providers.  Using this tracking system, Masters will be able to track orders and reduce the number of lost shipments.    

When you order medications,…

We are not a team because we work together. We are a team because we respect, trust, and care for each other. – Vala Afshar

I am the first person to admit that I don’t know much about a lot of different things. But I do know talent when I see it. And I could not be…